PARP inhibitorFDA-approvedSecond-line
Olaparib
How it works
Blocks an enzyme called PARP that helps repair DNA damage in cancer cells, making them more susceptible to cell death.
Cancer types
Ovarian Cancer— BRCA1/2-mutated
Pancreatic Cancer— BRCA1/2-mutated patients
Breast Cancer— BRCA1/2-mutated
Prostate Cancer— BRCA1/2-mutated
Efficacy
Olaparib has been shown to improve progression-free survival in BRCA1/2-mutated ovarian cancer patients.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Olaparib and Pembrolizumab for Advanced Uveal Melanoma | Melanoma | phase-2 | — | Source → |
| Testing Radiotherapy and Immunotherapy for Small Cell Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Testing Combination Therapy for Advanced Solid Tumors | Lung Cancer | phase-1 | — | Source → |
| Combining two treatments for advanced prostate cancer | Prostate Cancer | phase-2 | Median radiographic progression-free survival was 5.0 months, and median overall survival was 19.1 months. | Source → |
| Testing Olaparib for Ovarian Cancer Treatment | Ovarian Cancer | phase-3 | — | Source → |
| Olaparib Sensitivity in Colorectal Cancer | Colorectal Cancer | lab-study | — | Source → |
| Testing Combination Therapy for Recurrent Ovarian and Peritoneal Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Olaparib for Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | Leukemia | phase-2 | — | Source → |
| Olaparib Trial for Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| Pancreatic Cancer Treatment Trial | Pancreatic Cancer | phase-1 | — | Source → |
| Immunotherapy for Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| Olaparib and Abiraterone Combination Therapy for Advanced Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Testing a Combination of Two Oral Drugs for Advanced Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Combining SM08502 and Olaparib May Help Overcome Cancer Resistance | Ovarian Cancer | lab-study | — | Source → |
| New Treatment Options for Advanced Ovarian Cancer Patients | Ovarian Cancer | phase-3 | — | Source → |
| New Treatment Combination Shows Promise for Ovarian Cancer Patients | Ovarian Cancer | phase-2 | PFS36 rates are 47.4% (olaparib priming then olaparib-durvalumab), 48.7% (olaparib-cyclophosphamide then olaparib-durvalumab), and 35.1% (olaparib monotherapy). | Source → |
| Researchers Identify New Target to Enhance Prostate Cancer Treatment | Prostate Cancer | lab-study | — | Source → |
| Curcumin Analogue and Olaparib Combination Shows Promise in Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| New Combination Therapy Shows Promise in Treating Triple-Negative Breast Cancer | Breast Cancer | lab-study | The combination of Olaparib and Exemestane was able to achieve enhanced tumor growth inhibition in a murine xenograft model, greater than either drug employed as a single agent. | Source → |
| TTK protein linked to resistance in ovarian cancer treatment | Ovarian Cancer | lab-study | — | Source → |
| Combining Cancer Treatments May Help Prostate Cancer Patients | Prostate Cancer | lab-study | — | Source → |
| Combining Cancer Drugs Boosts Immune Response in Resistant Breast Cancer | Breast Cancer | lab-study | — | Source → |
| Rare Skin Condition Linked to Cancer Treatment | Ovarian Cancer | observational | — | Source → |
| Olaparib Monotherapy Shows Promise in Lung Cancer Treatment | Lung Cancer | meta-analysis | Olaparib monotherapy increased progression-free survival (PFS) level [ES= 7.76; 95% CI= 0.16 to 1.36; P=0.208]. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.